Orthobiologics

FDA approved Vericel’s MACI® for the repair of adult symptomatic single or multiple full-thickness cartilage defects of the knee....

Three-month safety data from a Phase I clinical trial in China for Cellular Biomedicine’s AlloJoin™ off-the-shelf allogeneic stem cell therapy in...

Study results demonstrated a high rate of clinical success from a combination of Biomatlante’s MBCP+™ synthetic bone graft plus mesenchymal stem...

curasan received FDA 510(k) clearance to market CERASORB Ortho FOAM synthetic bone material for the treatment of bone defects in the...

RTI Surgical’s C-Plus™ PEEK Interbody Fusion system is now indicated for use with allograft, including the company’s map3® cellular allogeneic bone graft. ...

Artoss announced FDA 510(k) clearance to market NanoBone® SBX Putty. ...

Bioventus launched DUROLANE® single-injection joint fluid therapy in Mexico, indicated for treatment of mild to moderate knee osteoarthritis. The product will be...

CMS assigned a unique HCPCS reimbursement code to Fidia Pharma’s HYMOVIS® highly viscoelastic, non-crosslinked hydrogel to treat knee osteoarthritis pain. ...

Bone Therapeutics will not pursue U.S. clinical development of PREOB® autologous cell therapy. In the U.S., priority will be given...

DiscGenics announced allowance of 9 additional patents, including two in the U.S. and seven in EU markets. The company is...